Publications by authors named "Y Y Kang"

9,620 Publications

Updated results on the integration of metal-organic framework with functional materials toward n-alkane for latent heat retention and reliability.

J Hazard Mater 2021 Sep 10;423(Pt B):127147. Epub 2021 Sep 10.

Department of Architecture and Architectural Engineering, Yonsei University, Seoul 03722, Republic of Korea. Electronic address:

Phase change composites are in high demand in thermal management systems. Various supporting materials, including nanocomposites, have been employed to develop shape-stable phase change materials (PCMs). As the reliability of most composite materials has mostly been studied right after the preparation with specific thermal cycling measurements, it is difficult to analyze the long-term leakage-resistance capability and energy retention capacity. Additionally, achieving multifunctional phase change composites is a significant challenge for single supporting materials. Herein, we provide a follow-up report on the thermal performance of hybrid material-supported n-alkane after a storage time of one year and 50 heating/cooling cycles. The interconnected hybrid material composed of a metal-organic framework (MOF) and graphite improved the shape/thermal stability of tetradecane (TD). The as-synthesized MOF/graphite/TD composites exhibited a high latent heat retention capacity of 84.2%, low leakage rate of 1.25%, and high PCM loading capacity, making them suitable for thermal management applications, such as industrial waste heat recovery systems. Furthermore, the intermolecular interactions and capillary forces between the hybrid materials and TD provided high stability and compatibility. Therefore, the as-prepared hybrid material fabricated in this study can be important in the development of multidirectional composite PCMs with comprehensive thermal characteristics.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhazmat.2021.127147DOI Listing
September 2021

A distinct association of inflammatory molecules with outcomes of COVID-19 in younger versus older adults.

Clin Immunol 2021 Sep 21:108857. Epub 2021 Sep 21.

Section of Rheumatology, Allergy & Immunology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA. Electronic address:

Aging can alter immunity affecting host defense. COVID-19 has the most devastating clinical outcomes in older adults, raising the implication of immune aging in determining its severity and mortality. We investigated biological predictors for clinical outcomes in a dataset of 13,642 ambulatory and hospitalized adult COVID-19 patients, including younger (age < 65, n = 566) and older (age ≥ 65, n = 717) subjects, with in-depth analyses of inflammatory molecules, cytokines and comorbidities. Disease severity and mortality in younger and older adults were associated with discrete immune mechanisms, including predominant T cell activation in younger adults, as measured by increased soluble IL-2 receptor alpha, and increased IL-10 in older adults although both groups also had shared inflammatory processes, including acute phase reactants, contributing to clinical outcomes. These observations suggest that progression to severe disease and death in COVID-19 may proceed by different immunologic mechanisms in younger versus older subjects and introduce the possibility of age-based immune directed therapies.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clim.2021.108857DOI Listing
September 2021

Sedation Effects Produced by a Ciprofol Initial Infusion or Bolus Dose Followed by Continuous Maintenance Infusion in Healthy Subjects: A Phase 1 Trial.

Adv Ther 2021 Sep 24. Epub 2021 Sep 24.

Clinical Trials Center, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Wuhou District, Chengdu, 610041, China.

Introduction: The effects of continuous infusions of ciprofol on its pharmacodynamic and pharmacokinetic properties and safety profiles in healthy Chinese subjects were evaluated.

Methods: In this open-label, randomized, two-way cross-over study, subjects received initial doses of continuous ciprofol/propofol as an infusion for 30 min in part 1 (n = 8) and a bolus dose in part 2 (n = 8) followed by maintenance infusions for a total of 4 h in part 1 and 12 h in part 2. Each subject participated in both parts with a washout time of at least 40 h.

Results: The safety and tolerability parameters of ciprofol were similar to those of propofol, and all treatment-emergent adverse events were mild. The incidences of injection pain and respiratory depression in subjects given ciprofol were lower than those receiving propofol. The pharmacokinetic parameters C, t, t, λz and MRT for ciprofol and propofol were similar, while CL, V and V were statistically significantly different. Pharmacodynamic parameters including the Richmond Agitation Sedation Scale and bispectral index profiles of ciprofol were similar to those of propofol.

Conclusion: Ciprofol has potential for clinical application for continuous intravenous infusion to maintain sedation for 12 h with the same safety, tolerability and efficacy as propofol.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-021-01914-4DOI Listing
September 2021

Observation of the Mass Difference between Neutral Charm-Meson Eigenstates.

Phys Rev Lett 2021 Sep;127(11):111801

Laboratoire Leprince-Ringuet, CNRS/IN2P3, Ecole Polytechnique, Institut Polytechnique de Paris, Palaiseau, France.

A measurement of mixing and CP violation in neutral charm mesons is performed using data reconstructed in proton-proton collisions collected by the LHCb experiment from 2016 to 2018, corresponding to an integrated luminosity of 5.4  fb^{-1}. A total of 30.6 million D^{0}→K_{S}^{0}π^{+}π^{-} decays are analyzed using a method optimized for the measurement of the mass difference between neutral charm-meson eigenstates. Allowing for CP violation in mixing and in the interference between mixing and decay, the mass and decay-width differences are measured to be x_{CP}=[3.97±0.46(stat)±0.29(syst)]×10^{-3} and y_{CP}=[4.59±1.20(stat)±0.85(syst)]×10^{-3}, respectively. The CP-violating parameters are measured as Δx=[-0.27±0.18(stat)±0.01(syst)]×10^{-3} and Δy=[0.20±0.36(stat)±0.13(syst)]×10^{-3}. This is the first observation of a nonzero mass difference in the D^{0} meson system, with a significance exceeding seven standard deviations. The data are consistent with CP symmetry and improve existing constraints on the associated parameters.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1103/PhysRevLett.127.111801DOI Listing
September 2021

Cross-protective efficacy of inactivated whole influenza vaccines against Korean Y280 and Y439 lineage H9N2 viruses in mice.

Vaccine 2021 Sep 20. Epub 2021 Sep 20.

Animal and Plant Quarantine Agency, Gimcheon, Republic of Korea. Electronic address:

Since June 2020, the Y280 lineage H9N2 virus, which is distinct from the previously endemic Y439 lineage, has been circulating in poultry in Korea. In this study, we developed two whole inactivated vaccines, rgHS314 and vac564, against the Y280 and Y439 lineages, respectively, and evaluated their immunogenicity and protective efficacy against homologous or heterologous viral challenge in mice. Serum neutralizing antibody titers in the rgHS314-vaccinated group were higher (68 ± 8.4 10log) than in the vac564-vaccinated group (18 ± 8.4 10log). In homologous challenge, rgHS314 conferred 100% protection, with no severe clinical signs, no body weight loss, and no viral replication in any tissues tested except the nasal turbinate. Viral replication in the lungs at 1, 3, 5, and 7 days post-infection (dpi) was significantly lower than in the sham group (p < 0.01). By contrast, all mice in the sham group were dead by 8 dpi with severe clinical signs and weight loss. Likewise, vac564 conferred 100% protection with no weight loss and with significantly lower viral replication in the lung than in the sham group at 3 dpi (p < 0.01). However, both vaccines showed partial protection in heterologous challenge. Our results suggest that both the rgHS314 and vac564 vaccines could be candidate vaccines for further evaluation in humans.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2021.09.028DOI Listing
September 2021
-->